AI Terminal
BerGenBio
Report Publication Announcement • Dec 8, 2022
3555_rns_2022-12-08_e6dac85c-a0ad-4512-a8a1-5ec8f0736f8d.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
BerGenBio to present at DNB's Nordic Healthcare Conference
BERGEN, Norway, December 8, 2022 – BerGenBio ASA (OSE: BGBIO), a clinicalstage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the 13th Annual DNB Nordic Healthcare Conference in Oslo, Norway, on Thursday, December 15, 2022, at 11:45am CET.
The presentation will be made available on the Company website in the presentations section on the day of the event:
www.bergenbio.com/investors/presentations/
-End-
Contacts
Martin Olin CEO, BerGenBio ASA [email protected]
Rune Skeie, CFO, BerGenBio ASA [email protected]
Investor Relations / Media Relations
Graham Morrell [email protected]
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5- 12 of the Norwegian Securities Trading Act.